ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,88%
Dow Jones
44 996,04
0,63%
DAX
21 727,20
0,48%
Brent Oil
76,095
0,23%
Bitcoin
105 451,10
1,65%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Kiniksa Pharmaceuticals International PLC (KNSA) Cours

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

NASDAQ
20,32
-0,34
( -1,65% )
Mis à jour : 19:31:10
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
20,32
Prix Achat
20,30
Prix Vente
20,33
Volume échangé
103 058
20,065 Fourchette du Jour 20,83
16,56 Plage de 52 semaines 28,15
Cap du marché
1,467B
Clôture Veille
20,66
Ouverture
20,83
Dernière Transaction
2
@
20.315
Dernière heure de transaction
19:31:10
Volume financier
US$ 2 091 801
VWAP
20,2973
Volume moyen (3 m)
398 658
Actions en circulation
72 201 565
Rendement du Dividende
-
Ratio Cours sur Bénéfices
103,38
Bénéfice par action (BPA)
0,2
Chiffre d'affairess
270,26M
Bénéfice net
14,08M

À propos de Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.kiniksa.com
Siège social
London, Gbr
Fondé
-
Kiniksa Pharmaceuticals International PLC est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker KNSA. Le dernier cours de clôture d'Kiniksa Pharmaceuticals était de US$20,66. Au cours de la dernière année, les actions de Kiniksa Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 16,56 à US$ 28,15.

Kiniksa Pharmaceuticals compte actuellement 72 201 565 actions en circulation. La capitalisation boursière d'Kiniksa Pharmaceuticals est de US$1,49 milliard. Kiniksa Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de 103.38.

Flux d'options Kiniksa Pharmaceuticals (KNSA)

Voir le flux d'options complet

Flux global

Baissier

Prime nette

-21k

Calls / Puts

100,00%

Ach. / Vent.

0,00%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

KNSA Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

15 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

13 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million ––...

13 Janvier 2025
GlobeNewswire Inc.

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on...

06 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

03 Décembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.562.8340080971719.7620.919.5277237120.39690393CS
40.321.62020.917.8258220119.56424742CS
12-2.76-11.958405545923.0823.51517.8239865820.38452436CS
26-5.98-22.737642585626.328.1517.8238752623.04455673CS
521.9310.49483414918.3928.1516.5639778721.64088057CS
1569.3585.232452142210.9728.157.3638915516.63966186CS
2605.3235.466666666715337.3639146816.66049826CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals share price?
The current share price of Kiniksa Pharmaceuticals is US$ 20,32
How many Kiniksa Pharmaceuticals shares are in issue?
Kiniksa Pharmaceuticals has 72 201 565 shares in issue
What is the market cap of Kiniksa Pharmaceuticals?
The market capitalisation of Kiniksa Pharmaceuticals is USD 1,49B
What is the 1 year trading range for Kiniksa Pharmaceuticals share price?
Kiniksa Pharmaceuticals has traded in the range of US$ 16,56 to US$ 28,15 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals?
The price to earnings ratio of Kiniksa Pharmaceuticals is 103,38
What is the cash to sales ratio of Kiniksa Pharmaceuticals?
The cash to sales ratio of Kiniksa Pharmaceuticals is 5,39
What is the reporting currency for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Kiniksa Pharmaceuticals?
The latest annual turnover of Kiniksa Pharmaceuticals is USD 270,26M
What is the latest annual profit for Kiniksa Pharmaceuticals?
The latest annual profit of Kiniksa Pharmaceuticals is USD 14,08M
What is the registered address of Kiniksa Pharmaceuticals?
The registered address for Kiniksa Pharmaceuticals is THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
What is the Kiniksa Pharmaceuticals website address?
The website address for Kiniksa Pharmaceuticals is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals operate in?
Kiniksa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FOXXFoxx Development Holdings Inc
US$ 10,32
(257,09%)
24,08M
AMODAlpha Modus Holdings Inc
US$ 3,69
(139,61%)
115,16M
TECXTectonic Therapeutic Inc
US$ 55,00
(113,84%)
4,31M
ACONAclarion Inc
US$ 17,88
(94,08%)
2,45M
ATHEAlterity Therapeutics Limited
US$ 4,47
(53,61%)
20,62M
CLEUChina Liberal Education Holdings Ltd
US$ 0,2212
(-97,15%)
183,21M
CRGXCARGO Therapeutics Inc
US$ 3,4025
(-74,20%)
16,82M
EVTVEnvirotech Vehicles Inc
US$ 0,372
(-44,23%)
3,13M
FATFAT Brands Inc
US$ 3,4988
(-40,40%)
220,01k
ZKINZK International Group Co Ltd
US$ 0,2983
(-38,56%)
2,09M
NVDANVIDIA Corporation
US$ 119,635
(-3,29%)
214,39M
CLEUChina Liberal Education Holdings Ltd
US$ 0,2212
(-97,15%)
183,21M
MGOLMGO Global Inc
US$ 0,1259
(23,80%)
145,16M
AMODAlpha Modus Holdings Inc
US$ 3,69
(139,61%)
114,04M
SPGCSacks Parente Golf Inc
US$ 0,8028
(36,07%)
105,86M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
KNSA
Kiniksa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces